Given the cross-talk among VEGF signaling, EGFR pathways, and hypoxia responses (38–42), adding anti-angiogenic agents in selected, stratified populations may remodel the tumor microenvironment (TME) and potentiate both immunotherapy and chemotherapy. This evidence concerns the gene EGFR and neoplasm.